Immuron Ltd (NASDAQ:IMRN, ASX:IMC) has returned record half-yearly sales for its gastrointestinal and digestive health supplement, Travelan®, which combats travellers' diarrhoea.
The record figures, amounting to A$2,334,969, mark a significant increase over previous periods.
Australian market leads the way
In Australia, Travelan's sales soared to A$1,853,048 in the first half of the financial year 2024, a substantial leap from A$260,205 in the corresponding period last year.
This 132% increase over the pre-pandemic peak in the first half of 2020 reflects the product's growing popularity, along with a partial accumulation of three months of backorders due to delayed Good Manufacturing Practice (GMP) clearance from the Therapeutic Goods Administration (TGA).
The company thinks another factor was travelling trends. The Australian Bureau of Statistics (ABS) reports that short-term resident returns in October 2023 were 47% higher than in October 2022, nearing pre-pandemic figures at 93% of October 2019 levels.
Promising trends for US despite challenges
In the US, Travelan’s sales reached A$481,920 in the first half of the current financial year, compared to A$295,411 in the same period of the preceding year.
Despite being 6% lower than pre-pandemic peak period sales in the first half of 2020, the figures are promising.
The International Trade Administration notes that total US citizen international visitor departures in September 2023 were 17% higher than in September 2022.
Specifically, Immuron's target markets saw departures in July through to September 2023 surpass pre-pandemic levels by 1%.
Following its successful Amazon launch on July 5, 2023, Immuron anticipates a strong growth in sales in the approach to the peak spring/summer travel season in the US.
The remarkable sales performance of Travelan in both the Australian and US markets underscores Immuron's growing influence in the global biopharmaceutical sector.
The company remains optimistic about sustaining and expanding this growth trajectory in the upcoming financial periods.